Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Japan first to approve Humira for pyoderma gangrenosum

Nov. 30, 2020

European Commission approves Dupixent for severe atopic dermatitis in children aged 6-11 years

Nov. 30, 2020

Genfleet Therapeutics describes new RIPK1 inhibitors

Nov. 27, 2020

InMed reports results from an initial phase I trial of INM-755 healthy subjects

Nov. 26, 2020

Positive topline data from phase IIb study of ARQ-154 in scalp and body psoriasis

Nov. 24, 2020

Promore reports phase IIb data on ropocamptide for venous leg ulcers

Nov. 20, 2020

JAK inhibitor prodrugs discovered at Theravance Biopharma

Nov. 19, 2020

Tofacitinib demonstrates long-term safety and efficacy in refractory dermatomyositis

Nov. 17, 2020

Phase III trial shows efficacy and safety of intravenous immunoglobulin in treating dermatomyositis

Nov. 17, 2020

Designed Cells, Chungbuk National University patent stem cell-derived exosome-rich culture medium

Nov. 17, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...